In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans

Toxicology and Applied Pharmacology

Volumn 136, Issue 2, 1996, Pages 289-306

  Reitz, Richard H ^a   Gargas, Michael L ^b   Mendrala, Alan L ^c   Schumann, Alan M ^c  

^a RHR Consulting Services   (United States)

^b McLaren Hart Environ Services   (United States)

^c DOW CHEMICAL COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TETRACHLOROETHYLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MODEL; MOUSE; NONHUMAN; PHARMACOKINETICS; RAT; TOXICOKINETICS; XENOBIOTIC METABOLISM;

EID: 0030068148     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.0036     Document Type: Article

References (50)

1. Agin, G. L., and Blau, G. E. (1982). Application of DACSL (Dow Advanced Continuous Simulation Language) to the design and application of chemical reactor systems. Am. Inst. Chem. Eng. Symp. Ser. 78 (No. 214) 108-118.
2. Andersen, M. E. (1987). Tissue dosimetry in risk assessment, or what's the problem here anyway? In Pharmacokinetics in Risk Assessment, Vol. 8, Drinking Water and Health, pp. 8-26. National Academy Press, Washington, DC.
3. Andersen, M. E., Clewell, H. J., Gargas, M. L., Smith, F. A., and Reitz, R. H. (1987). Physiologically-based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87, 185-205.
4. Andersen, M. E., Clewell, H. J., Gargas, M. L., MacNaughton, M. G., Reitz, R. H., Nolan, R. J., and McKenna, M. J. (1991). Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol. Appl. Pharmacol. 108, 14-27.
5. Beaune, P., Kremers, P. G., Kaminsky, L. W., DeGraeve, J., and Guengerich, F. P. (1986). Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab. Dispos. 14, 437-442.
6. Bocker, R. H., and Guengerich, F. P., (1986). Oxidation of 4-aryl-and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J. Med. Chem. 29, 1596-1603.
7. Bogen, K. T., Hall, L. C., McKone, T. E., Layton, D. W., and Patton, S. E. (1987). Health Risk Assessment of Tetrachloroethylene (PCE) in California Drinking Water. Prepared for California Public Health Foundation by the Environmental Sciences Division of Lawrence Livermore National Laboratory, P. O. Box 5507, Livermore, CA 94550.
8. Bogen, K. T., and McKone, T. E. (1988). Linking indoor air and pharmacokinetic models to assess tetrachlorethylene risk. Risk Anal. 8, 509-520.
9. Chen, C. W., and Blancato, J. N. (1987). Pharmacokinetics in Risk Assessment, Vol. 8, Drinking Water and Health, pp. 369-390. National Academy Press, Washington, DC.
10. Corley, R. A., Mendrala, A. M., Smith, F. A., Staats, D. A., Gargas, M. L., Conolly, R. B., Andersen, M. E., and Reitz, R. H. (1990). Development of a physiologically-based pharmacokinetic based model for chloroform. Toxicol. Appl. Pharmacol. 103, 512-527.
11. Dekant, W., Metzler, M., and Henschler, D. (1986). Identification of S-1,2,2-trichlorovinyl-N-acetylcysteine as urinary metabolite to tetrachloroethylene: Bioactivation through glutathione conjugation as a possible explanation of its nephrocarcinogenicity. J. Biochem. Toxicol. 1, 57-72.
12. ECETOC Technical Report 37 (1990). Tetrachloroethylene: Assessment of Human Carcinogenic Hazard, ISSN-0773-8072-37. ECETOC, Brussels, Belgium.
13. Environmental Protection Agency (EPA) (1985). Health Assessment Document for Tetrachloroethylene (Perchloroethylene): Final Report, EPA/ 600/8-82/005F (available from National Technical Information Service, Springfield, VA).
14. Environmental Protection Agency (EPA) (1986). Addendum to the Health Assessment Document for Tetrachloroethylene (Perchloroethylene, PERC, PCE), EPA/600/8-82/005FA. External review draft (available from National Technical Information Service, Springfield, VA as publication PB86-174489).
15. Fernandez, J., Guberan, E., and Caperos, J. (1976). Experimental human exposures to tetrachloroethylene vapor and elimination in breath after inhalation. Am. Ind. Hyg. Assoc. J. 24, 143-150.
16. Gargas, M. L. (1988). Tissue Solubilities and Biotransformation Rates of Halocarbons: Experimental Determinations and Quantitative Modeling. A dissertation submitted to Wright State University, Dayton, OH.
17. Gargas, M. L., Andersen, M. E., and Clewell, H. J., III. (1986). A physiologically-based simulation approach for determining metabolic constants from gas uptake data. Toxicol. Appl. Pharmacol. 86, 341-352.
18. Gargas, M. L., Burgess, R. J., Voisard, D. E., Cason, G. H., and Andersen, M. E. (1989). Partition coefficients of low molecular weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 98, 87-99.
19. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., and Waxman, D. J. (1986a). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060.
20. Guengerich, F. P., Muller-Enoch, D., and Blair, I. A. (1986b). Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30, 287-295.
21. Hall, S. D., Guengerich, F. P., Branch, R. A., and Wilkinson, G. R. (1987). Characterization and inhibition of mephenytoin 4-hydroxylase in human liver microsomes. J. Pharmacol. Exp. Ther. 240, 216-222.
22. Hattis, D., White, P., and Koch, P. (1993). Uncertainties in pharmacokinetic modeling for perchloroethylene: II. Comparison of model predictions with data for a variety of different parameters. Risk Anal. 13, 599-610.
23. Hattis, D., White, P., Marmorstein, L., and Koch, P. (1990). Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparisons of model structure, parameters, and predictions for low-dose metabolism for models derived by different authors. Risk Anal. 10, 449-458.
24. Hattis, D., Tuler, S., Finkelstein, L., and Luo, Z. Q. (1986). A pharmoacokinetic/Mechanisms-Based Analysis of the Carcinogenic Risk of Perchloroethylene. MIT Center for Technology, Policy, and Industrial Development, CTPID 86-7, Cambridge, MA.
25. Herren-Freund, S. L., Pereira, M. A., and Olson, G. (1987). The carcinogenicity of trichloroethylene and its metabolites, trichloroacetic acid and dichloroacetic acid, in mouse liver. Toxicol. Appl. Pharmacol. 90, 183-189.
26. Howe, R. B. (1983). GLOBAL83: An experimental program developed for the U.S. Environmental Protection Agency as an update to GLOBAL82.
27. Howe, R. B., and Crump, K. S. (1982). GLOBAL83: A computer program to extrapolate quantal animal toxicity data to low doses (May, 1982). OSHA Contract 41USC252C3.
28. Ikeda, M., Ohtsuji, H., Imamura, T., and Komoike, Y. (1972). Urinary excretion of total trichloro compounds, trichloroethanol, and trichloroacetic acid as a measure of exposure to trichloroethylene and tetrachloroethylene. Br. J. Ind. Med. 29, 328-333.
29. Knodell, R. G., Hall, S. D., Winkingon, G. R., and Guengerich, F. P. (1987). Hepatic metabolism of tolbutamide: In vivo characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241, 1112-1119.
30. Monster, A. C., Boersma, G., and Steenweg, H. (1979). Kinetics of tetrachloroethylene in volunteers; Influence of exposure concentration and workload. Int. Arch. Occup. Environ. Health 42, 303-309.
31. Monster, A. C. (1984). Tetrachloroethylene. In Biological Monitoring and Surveillance of Workers Exposed to Chemicals (A. Aitio, V. Riihimaki, and H. Vainio, Eds.), pp. 131-139, McGraw-Hill, New York.
32. Muller, G., Spassovski, M., and Henschler, D. (1974). Metabolism of trichloroethylene in man: II Pharmacokinetics of metabolites. Arch. Toxicol. 32, 283-295.
33. National Cancer Institute (NCI) (1977). Bioassay of Tetrachloroethylene for Possible Carcinogenicity. DHEW Publication (NIH) 77-813. U.S. Department of Health, Education, and Welfare, Public Health Service, NIH, Bethesda, MD.
34. 1 Mice (inhalation Studies). DHSS-NIH Report 85-2657, NIH, Bethesda, MD.
35. Ohtsuki, T., Sato, K., Koizumi, A., Kumai, M., and Ikeda, M. (1983). Limited capacity of humans to metabolize tetrachloroethylene. Int. Arch. Occup. Environ. Health 51, 381-390.
36. 14C)ethylene following oral and inhalation exposure in rats. Toxicol. Appl. Pharmacol. 51, 465-474.
37. Rampy, L. W., Quast, J. F., Balmer, M. F., Leong, B. K. J., and Gehring, P. J. (1978). Results of a long term inhalation toxicology study on rats of 1,1,1-trichloroethane and perchloroethylene formulations. In Proceedings of the First International Congress on Toxicology (G. L. Plaa, and W. A. M. Duncan, Eds.) pp. 562-571. Academic Press, New York.
38. Ramsey, J. R., and Andersen, M. E. (1984). A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol 73, 159-175.
39. Raucy, J. L., J. C. Kraner, and J. M. Lasker (1993). Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit. Rev. Toxicol. 23, 1-20.
40. Reitz, R. H., McDougal, J. N., Himmelstein, M. W., Nolan, R. J., and Schumann, A. M. (1988). Physiologically-based pharmacokinetic modeling with methylchloroform; Implications for interspecies, high dose/low dose and dose/route extrapolations. Toxicol. Appl. Pharmacol. 95, 185-199.
41. Reitz, R. H., Mendrala, A. L., and Guengerich, F. P. (1989). In vitro metabolism of methylene chloride in human and animal tissues: Use in physiologically-based pharmacokinetic models. Toxicol. Appl. Pharmacol. 97, 230-246.
42. Reitz, R. H., Mendrala, A. M., Corley, R. A., Quast, J. F., Gargas, M. L., Andersen, M. E., Staats, D. A., and Conolly, R. B. (1990). Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. Toxicol. Appl. Pharmacol. 105, 443-459.
43. Reitz, R. H., Gargas, M. L., Andersen, M. E., Provan, W. M., and Green, T. L. (1996). Predicting cancer risk from vinyl chloride exposure with a physiologically-based pharmacokinetic model. Toxicol. Appl. Pharmacol., in press.
44. Rowe, V. K., McCollister, D. D., Spencer, H. C., Adams, E. M., and Irish, D. D. (1952). Vapor toxicity of tetrachloroethylene for laboratory animals and human subjects. Arch. Ind. Hyg. Occup. Med. 5, 566-579.
45. Sato, A., and Nakajima, T. (1979). Partition coefficients of some aromatic hydrocarbons and ketones in water, blood, and oil. Br. J. Ind. Med. 36, 231-234.
46. Schumann, A. M., Quast, J. F., and Watanabe, P. G. (1980). The pharmacokinetics and macromolecular interactions of perchloroethylene in mice and rats. Toxicol. Appl. Pharmacol. 55, 207-219.
47. Schwetz, B. A., Leong, B. K., and Gehring, P. J. (1975). The effect of maternally inhaled trichloroethylene, perchloroethylene, methylchloroform, and methylene chloride on embryonal and fetal development in mice and rats. Toxicol. Appl. Pharmacol. 32, 84-96.
48. Science Advisory Board (1991). Health Effects Assessment of Perchloroethylene: Review of the Office of Research and Development's Draft Document "Response to Issues and Data Submissions on the Carcinogenicity of Perchloroethylene (EPA/600/6-91/002A) by the Environmental Health Committee. EPA-SAB-EHC-91-013, August, 1991.
49. Tuey, D. B., and Matthews, H. B. (1980). Use of a physiological compartmental model for the rat to describe the pharmacokinetics of several chlorinated biphenyls in the mouse. Drug Metab. Dispos., 8, 397-403.
50. Ward, R. C., Travis, C. C., Hetrick, D. M., Andersen, M. E., and Gargas, M. L. (1988). Pharmacokinetics of tetrachloroethylene. Toxicol. Appl. Pharmacol. 93, 108-117.